On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies
Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.
Authors
- Maryia Zhdanava (ORCID: https://orcid.org/0000-0002-7995-2578)
- Timothy Fitzgerald (ORCID: https://orcid.org/0000-0003-3441-1708)
- Samuel Schwartzbein
- Dominic Pilon
- Steven R Feldman
- Porpong Boonmak
- Béatrice Libchaber
Institutions
- Johnson & Johnson (United States) (US)
- Wake Forest University (US)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1080/09546634.2026.2631903
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00